Company intelligence / Profile preview
Pop Test Cortisol
Cliffside Park, New Jersey, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Pop Test Cortisol has demonstrated, in pre-clinical trials, that the small molecule Org34517 is effective as a chemotherapy sensitizer in triple negative breast cancer. Org34517 already completed phase 2 studies for neuropsychiatric disorders, but oncology indications are currently in pre-clinical stage. The company has also developed FDA-registered saliva-based diagnostics for cortisol and other biomarkers.
- Therapeutic areas
- PsychiatryOncologyEndocrinology
- Modalities
- Small moleculeDeviceLateral flow diagnostic
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Kurume University School of Medicine (research collaboration)
Beyond the preview
Go deeper on Pop Test Cortisol.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pop Test Cortisol.